BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Sep 20, 2012
 |  BC Extra  |  Company News

MacroGenics, Servier in second cancer mAb option deal

MacroGenics Inc. (Rockville, Md.) granted Servier (Neuilly-sur-Seine, France) an exclusive option to license rights to develop and commercialize preclinical mAbs against three undisclosed cancer targets outside North America, Japan, Korea and India. MacroGenics will receive $20 million up front...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >